Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.
Day Range6.200 - 6.940 | 52 Wk Range3.502 - 42.000 | Open / Close6.560 / 6.430 | Float / Outstanding1.608M / 1.616M |
Vol / Avg.17.123K / 385.332K | Mkt Cap10.020M | P/E- | 50d Avg. Price7.730 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float1.608M | EPS-17.000 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-21 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.500 | ||||||
REV | 4.710M | 0 | -4.710M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Quoin Pharmaceuticals (NASDAQ:QNRX), Synaptogenix (NASDAQ:SNPX) and Imunon (NASDAQ:IMNN).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.